-
公开(公告)号：WO2016015158A1
公开(公告)日：2016-02-04
申请号：PCT/CA2015/050723
申请日：2015-07-30
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： HUANG, Ling , MUTHUSWAMY, Senthil
CPC classification number: C12N5/0678 , C12N5/0062 , C12N5/0676 , C12N5/0693 , C12N2500/38 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/15 , C12N2501/16 , C12N2501/33 , C12N2501/385 , C12N2501/999 , C12N2506/02 , C12N2533/90 , G01N33/5011 , G01N33/507 , G01N33/5088
Abstract: There is provided herein cell culture mediums for generating organoids, including tumour organoids.
Abstract translation: 本文提供了用于产生组织细胞的细胞培养基，包括肿瘤组织细胞。
-
公开(公告)号：WO2015192215A1
公开(公告)日：2015-12-23
申请号：PCT/CA2015/000397
申请日：2015-06-18
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： CHEN, Juan , ZHENG, Gang , CUI, Liyang
CPC classification number: B82Y5/00 , A61K9/1075 , A61K9/5169 , A61K31/337 , A61K31/404 , A61K41/0071 , A61K41/0076 , A61K47/42 , A61K47/544 , A61K47/6907 , A61K49/0036 , Y10S977/773 , Y10S977/801 , Y10S977/906 , Y10S977/915
Abstract: There is provided herein a nanovesicle comprising a monolayer of phospholipid, porphyrin-phospholipid conjugate and a peptide encapsulating a hydrophobic core, wherein the peptide comprises an amino acid sequence capable of forming at least one amphipathic α-helix; the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipid; the molar % of porphyrin-phospholipid conjugate to phospholipid is 35% or less; the nanovesicle is 35nm in diameter or less.
Abstract translation: 本文提供了包含磷脂单层，卟啉 - 磷脂缀合物和封装疏水核心的肽的纳米囊，其中肽包含能够形成至少一个两亲性α-螺旋的氨基酸序列; 卟啉 - 磷脂缀合物包含一个磷脂的一个卟啉，卟啉衍生物或卟啉类似物共价连接到脂质侧链，优选在sn-1或sn-2位; 卟啉 - 磷脂缀合物对磷脂的摩尔％为35％以下; 纳米囊直径为35nm或更小。
-
公开(公告)号：WO2015149188A1
公开(公告)日：2015-10-08
申请号：PCT/CA2015/050277
申请日：2015-04-07
Inventor： WU, Xiaoyu , GORDIJO, Claudia Regina , ABBASI, Azhar Z. , PRASAD, Preethy , DACOSTA, Ralph , MAEDA, Azusa
IPC: A61K9/14 , A61K47/02 , A61K47/30 , A61K47/42 , A61L31/12 , A61N5/00 , A61P35/00 , C01B13/00 , C01G1/02 , C07H21/00 , C07K17/00
CPC classification number: A61K41/0038 , A61K9/0019 , A61K9/14 , A61K9/5146 , A61K9/5169 , A61K33/32 , A61K47/32 , A61K47/34 , A61K47/42 , A61N5/10 , A61N5/1001 , A61N2005/1021 , A61N2005/1098 , C01G45/02 , C01P2002/72 , C01P2002/84 , C01P2004/04 , C01P2004/24 , C01P2004/64 , C01P2006/22
Abstract: Disclosed herein are multifunctional nanoparticle compositions. The compositions can be useful for the treatment of cancer by enhancing the anti-tumor effectiveness of radiation directed to a tissue, cell or a tumor and the methods of use thereof. The multifunctional nanoparticle composition comprises a metal oxide nanoparticle core;a functional coating on the surface of the metal oxide nanoparticle core; and a matrix carrier in which the coated nanoparticle is embedded.
Abstract translation: 本文公开了多功能纳米颗粒组合物。 该组合物可用于通过增强针对组织，细胞或肿瘤的辐射的抗肿瘤效力及其使用方法来治疗癌症。 所述多功能纳米颗粒组合物包含金属氧化物纳米颗粒核心;金属氧化物纳米颗粒核心表面上的功能涂层; 和其中嵌入被覆纳米颗粒的基质载体。
-
公开(公告)号：WO2015051447A1
公开(公告)日：2015-04-16
申请号：PCT/CA2014/000733
申请日：2014-10-07
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： SCHIMMER, Aaron David , BUHAJCZUK, Dannie
IPC: C07D311/58 , A61K31/352 , A61K36/48 , A61P35/00 , C07D311/22
CPC classification number: A61K31/352 , A61K31/337 , A61K31/475 , A61K36/48 , A61K45/06 , C07D311/22 , C07D311/58 , A61K2300/00
Abstract: A compound of Formula I and/or II and/or a composition comprising a compound of Formula I and/or II is described as well as uses of said compounds and compositions for inhibiting microtubule polymerization, inducing lysosome disruption and/or treating a cancer, including a hematological cancer such as leukemia.
Abstract translation: 描述式I和/或II化合物和/或包含式I和/或II化合物的组合物以及所述化合物和组合物用于抑制微管聚合，诱导溶酶体破坏和/或治疗癌症的用途， 包括血液癌症如白血病。
-
125.发明申请BIOMARKERS FOR EARLY DETERMINATION OF A CRITICAL OR LIFE THREATENING RESPONSE TO ILLNESS AND/OR TREATMENT RESPONSE 审中-公开生物标志物早期确定关键或生命对无效和/或治疗反应的反应
公开(公告)号：WO2015031996A1
公开(公告)日：2015-03-12
申请号：PCT/CA2014/050841
申请日：2014-09-05
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： KAIN, Kevin , LILES, W. Conrad , ERDMAN, Laura , CONROY, Andrea
IPC: G01N33/543 , C40B30/04 , C40B40/10 , G01N33/48
CPC classification number: G01N33/6842 , G01N2800/50 , G01N2800/52 , Y02A50/53 , Y02A50/56 , Y02A50/58
Abstract: The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness.
Abstract translation: 本发明涉及使用新的生物标志物和生物标志物组合，其可用于早期确定个体对疾病的危及生命和/或威胁生命的反应和/或预测所述疾病的结果。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于确定个体对疾病的关键和/或威胁生命的反应。 在一些实施方案中，生物标志物和生物标志物组合是不可知的，并且独立于疾病的原因或性质的预先识别和/或确定。 在一些实施方案中，生物标志物和生物标志物组合可用于选择治疗和/或监测具有严重疾病的个体的治疗干预的有效性。
-
Patent Agency Ranking
公开(公告)号：WO2015021528A1
公开(公告)日：2015-02-19
申请号：PCT/CA2014/000615
申请日：2014-08-12
Applicant: UNIVERSITY HEALTH NETWORK
CPC classification number: G08B21/245 , G07C9/00111
Abstract: Disclosed herein are different embodiments of a hand hygiene compliance system, beacon, wearable monitor and kit.
Abstract translation: 本文公开了手卫生一致性系统，信标，可穿戴式监视器和套件的不同实施例。
-
127.发明申请METHOD AND SYSTEM FOR AUTOMATED QUALITY ASSURANCE AND AUTOMATED TREATMENT PLANNING IN RADIATION THERAPY 审中-公开辐射治疗自动质量保证和自动治疗规划方法与系统
公开(公告)号：WO2014197994A1
公开(公告)日：2014-12-18
申请号：PCT/CA2014/050551
申请日：2014-06-12
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： PURDIE, Thomas G. , MCINTOSH, Christopher , SVISTOUN, Igor
CPC classification number: G06F19/327 , A61N5/103 , A61N5/1038 , A61N5/1048 , A61N2005/1041 , G06F19/00 , G06F19/3456 , G06F19/3481 , G16H40/20
Abstract: Methods and systems for evaluating a proposed treatment plan for radiation therapy, for evaluating one or more delineated regions of interest for radiation therapy, and/or for generating a proposed treatment plan for radiation therapy. Machine learning based on historical data may be used.
Abstract translation: 用于评估放射治疗计划的治疗计划的方法和系统，用于评估放射治疗的一个或多个所划定的感兴趣区域和/或用于产生用于放射治疗的拟议治疗计划。 可以使用基于历史数据的机器学习。
-
公开(公告)号：WO2014191837A3
公开(公告)日：2014-12-04
申请号：PCT/IB2014/001748
申请日：2014-05-05
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： NANTHAKUMAR, Kumaraswamy
IPC: A61K31/4178 , A61K31/422 , A61P9/00 , A61P9/06
Abstract: The present description relates to methods of administering effective amounts of an anti-arrhythmic agent, e.g., dantrolene, azumolene or a pharmaceutically acceptable salt thereof, for the acute treatment of cardiac arrhythmias, e.g., atrial fibrillation, premature ventricular contraction, ventricular tachycardia or ventricular fibrillation, and prevention of subsequent cardiac arrhythmias, wherein the methods effectuate a reduction in morbidity and mortality.
-
129.发明申请SYSTEM AND METHOD FOR DECREMENT EVOKED POTENTIAL (DEEP) MAPPING TO IDENTIFY CRITICAL COMPONENTS OF THE ARRYTHMOGENIC CIRCUIT IN CARDIAC ARRHYTHMIAS 审中-公开系统和方法用于识别心脏电生理发生神经元电路的关键组件的潜在可能（深层）映射
公开(公告)号：WO2014183206A1
公开(公告)日：2014-11-20
申请号：PCT/CA2014/000438
申请日：2014-05-16
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： NANTHAKUMAR, Kumaraswamy , DOWNAR, Eugene , MASSE, Stephane
IPC: A61B5/0472 , A61B5/042 , A61B5/0432 , A61B5/0452
CPC classification number: A61B34/10 , A61B5/042 , A61B5/0422 , A61B5/0452 , A61B5/0464 , A61B5/0472 , A61B5/6852 , A61B5/686 , A61B5/6869 , A61B2034/105 , A61B2505/05
Abstract: Various embodiments are described herein for a system and a method for identifying the arrhythmogenic circuit of a patient or subject. In one embodiment, the method comprises obtaining data for electrograms recorded at various locations of the heart while programmed ventricular pacing with extra stimuli was performed, obtaining decrement values for at least two different locations of the heart using the recorded electrograms, generating at least a portion of a decrement map using the decrement values, and identifying the arrhythmogenic circuit based on electrograms having significant decremental properties.
Abstract translation: 本文描述了用于识别患者或受试者的致心律失常电路的系统和方法。 在一个实施例中，该方法包括获得记录在心脏的各个位置处的电描记图的数据，同时执行具有额外刺激的程序性心室起搏，使用所记录的电描记图获得心脏的至少两个不同位置的递减值，产生至少一部分 的减量图，并且基于具有显着递减特性的电图识别心律失常电路。
-
130.发明申请METHODS AND COMPOSITIONS FOR GENERATING CHONDROCYTE LINEAGE CELLS AND/OR CARTILAGE LIKE TISSUE 审中-公开用于产生肝细胞线粒细胞和/或软骨样组织的方法和组合物
公开(公告)号：WO2014161075A1
公开(公告)日：2014-10-09
申请号：PCT/CA2014/000312
申请日：2014-04-02
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： KELLER, Gordon , CRAFT, April M.
CPC classification number: A61K35/32 , C12N5/0655 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/415 , C12N2501/999 , C12N2503/02 , C12N2506/02 , C12N2506/03 , G01N33/5044
Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.
Abstract translation: 一种用于产生软骨细胞和/或软骨的方法，任选地关节像非增生性软骨细胞和/或软骨样组织和/或肥大软骨细胞样细胞和/或软骨样组织，所述方法包括：a。 培养原始条纹状中胚层群体，任选地具有CD56 +，PDGFRα+ KDR-原始条纹样中胚层群体，其中傍轴中胚层指定混合物，包括：i。 FGF激动剂; II。 BMP抑制剂; 任选地，Noggin，LDN-193189，Dorsomorphin; 和iii。 任选地一种或多种TGFβ抑制剂，任选的SB431524; 和Wnt抑制剂，任选地DKK1，IWP2或XAV939; 指定表达细胞表面CD73，CD105和/或PDGFR-β的近轴中胚层群; 湾 产生软骨细胞前体群体，包括：i。 以高细胞密度任选地在无血清或含血清培养基中培养表达CD73，CD105和/或PDGFR-β的近轴中胚层群; II。 在血清游离培养基中培养具有TGFbeta3激动剂的高细胞密度CD73 +，CD105 +和/或PDGFRβ+近轴中胚层群体以产生高细胞密度Sox9 +，胶原蛋白+2软骨细胞前体种群; 和c。 我是 用TGFbeta3激动剂长时间培养高细胞密度Sox9 +，胶原蛋白+软骨细胞前体种群，以产生关节性非肥大软骨细胞和/或软骨样组织; 或ii。 用BMP4激动剂长时间培养高细胞密度的Sox9 +胶原蛋白2 +软骨细胞前体群体，以产生肥大的软骨细胞样细胞和/或软骨样组织。
-
-
-
-
-
-
-
-
-
Search Results
1331
records
(took 0.048 seconds)
